GlassScriptPhysician profile
Lorayne A Chua
NPI 1700237914
$1,006.66
in general payments reported to CMS, 2019-2025
22 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.51 · 2024: $400 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $155.75 | 2024-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $103.62 | 2023-2025 | Ozempic, Rybelsus |
| Amphastar Pharmaceuticals, INC. | $79.23 | 2024 | Baqsimi |
| Medtronic, INC. | $76.36 | 2024-2025 | Minimed 780g, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.89 | 2024-2025 | Jardiance |
| Pfizer INC. | $74.07 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $73.89 | 2025 | |
| Recordati_rare_diseases_inc. | $46.72 | 2025 | Isturisa |
| Chiesi USA, INC. | $42.71 | 2024-2025 | Mycapssa |
| Tandem Diabetes Care, INC. | $31.50 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $29.53 | 2025 | Yorvipath |
| Almatica Pharma LLC | $26.76 | 2025 | Teriparatide |
| Radius Health, INC. | $25.47 | 2025 | Tymlos |
| Dexcom, INC. | $22.70 | 2024 | Dexcom G6 Transmitter |
| Fresenius Kabi USA, LLC | $22.66 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $20.06 | 2025 | Vykat Xr |
| Corcept Therapeutics | $18.54 | 2024 | Korlym |
| Kyowa Kirin, INC. | $18.40 | 2024 | Crysvita |
| Lilly USA, LLC | $16.83 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $16.02 | 2025 | |
| Beta Bionics, INC. | $15.53 | 2024 | Ilet Bionic Pancreas |
| Neurocrine Biosciences, INC. | $15.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorayne Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.